The digital revolution has in recent years transformed the global healthcare sector. The emergence of innovative technology has given rise to a network of diagnostic devices that can be used to generate, collect, and analyze huge volume of medical data. This in turn allows physicians to better measure and observe patients’ health, making diagnosis processes more efficient and accurate. Yet there are still plenty of gaps in diagnostic technology. For example, the recent pandemic underscores the demand for more options for effective and comprehensive detections systems for viruses and bacteria linked to respiratory infections. As such, Avalon has joined hands with researchers at top universities in Hong Kong to develop solutions aimed at enhancing early detection of conditions from COVID-19 to genetic diseases to cancer.
The market has long been lacking an all-in-one, comprehensive diagnostic system that is both effective and efficient in many ways. Now we are proud to present our innovative solution to the market.Dr Terence Lau
Co-Founder and President
Emerging Viral Diagnostics (HK) Limited
Avalon Automated Multiplex System (AAMST) is a comprehensive detection system that allows Point-of-Care Testing (POCT) in a low cost yet effective manner and supports a wide range of applications.
AAMST has only 3 major components:
Understand your genes for better health
Our health monitoring service goes beyond genetic test results into offering personalized guidance from our team of medical professionals, with the goal of helping you maintain lifelong health. We strive to achieve this through the following features that distinguish us from similar genome sequencing services available globally.
Sogen – Preventive Health Management
Developed by our team at Avalon Genomics, Sogen examines and analyzes the genetic risks of over 30 common conditions, including cancers and autoimmune diseases, in three easy steps. In addition, it provides a report with customized health improvement advice which allows you to take precautionary measures to reduce the chances of disease manifestation.
We are developing cancer diagnosis solution that is ultra-fast, blood-based and label-free.
The primary goal for the team at Conzeb is to address challenges faced by the medical community in cancer diagnostics and treatment monitoring, as current technologies adopted in this field are often costly, time-consuming and expert-dependent. The project, started at the University of Hong Kong and it’s now part of the Avalon platform, focuses on developing cancer diagnostic tools based on our revolutionary, patented ultra-fast optical imaging technologies – ATOM and FACED – for label-free, blood-based single-cell imaging. Together with our ultra-high speed microfluidics and deep cyto-analytics, our technologies can be served as a big-data single-cell data generator – serving the needs of cost-effective, real-time analysis of thousands to millions of cells for each patient.